Prescription medication, when used properly and safely, can provide needed relief to consumers suffering a wide range of illnesses or physical conditions. However, those medications must be marketed and advertised properly. That apparently wasn’t the case for a antipsychotic prescription drug manufactured Bristol-Myers Squibb (BMS). As a result, the company has agreed to pay $19.5 million in a settlement with 42 states and the District of Columbia. [More]
resolving the issues
Bristol-Myers Squibb Agrees To Pay $19.5M Over Improper Marketing Of Medication
By 12.8.16 — Updated: 12.12.16
